Efficacy of Lenvatinib versus Bevacizumab in Triple Therapy with Immune Checkpoint Inhibitors and Interventional Therapy for Hepatocellular Carcinoma with Macrovascular Invasion: A Multi-Center Real-World Retrospective Study
Background Hepatocellular carcinoma (HCC) patients with macrovascular invasion (MaVI) continue to experience a dismal prognosis and the optimal drug combination choices remain undefined. The aim of this study was to compare the clinical efficacy and safety of lenvatinib-based triple therapy versus bevacizumab-based tri...